Publications by authors named "Ko Ryo"

Claim this Profile
C
Correlation between cancer cachexia and psychosocial impact in older patients with advanced lung cancer undergoing chemotherapy.
Rika Sato, Tateaki Naito, Haruyasu Murakami, Shota Omori, Haruki Kobayashi, Ryo Ko

Asia Pac J Oncol Nurs· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial Patient Characteristics Associated With Ineligibility for Second-Line Therapy After Progression on First-Line Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.
Hiroaki Kodama, Haruyasu Murakami, Nobuaki Mamesaya, Haruki Kobayashi, Kazushige Wakuda, Ryo Ko

Thorac Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing.
Nobuaki Mamesaya, Keita Mori, Haruki Kobayashi, Shota Omori, Ryo Ko

Int J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of FDG-PET/CT findings with adequate tissue samples for gene panel testing in transbronchial lung biopsy and endobronchial ultrasound-guided transbronchial needle aspiration.
Akiko Tamura, Ryo Ko, Hirotsugu Kenmotsu, Takuya Kawata, Suguru Matsuda

Respir Investig· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Cancer Cachexia on the Efficacy and Treatment Delivery of Chemotherapy in Older Patients With Advanced Small Cell Lung Cancer.
Michitoshi Yabe, Tateaki Naito, Suguru Matsuda, Meiko Morita, Motoki Sekikawa, Ryo Ko

Thorac Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Status of Multimodal Therapy for Oligometastatic Disease, Induced Oligometastatic Disease, and Oligo-Progressive Disease in -Mutated Non-Small-Cell Lung Cancer.
Taichi Miyawaki, Hirotsugu Kenmotsu, Ryo Ko, Masaki Oshima, Takehito Shukuya

Cancers (Basel)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deterioration of performance status before administration of chemotherapy as a prognostic factor in untreated advanced non-small cell lung cancer.
Kenju Ando, Hirotsugu Kenmotsu, Yuichiro Nishibori, Akiko Tamura, Suguru Matsuda, Ryo Ko

Cancer Treat Res Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Desensitizing Effect of Intra-Tumoral GDF-15 on Immunotherapy in Patients With Advanced Non-Small Cell Lung Cancer.
Naoya Nishioka, Tateaki Naito, Takashi Sugino, Koji Muramatsu, Shigeki Nishihara, Ryo Ko

Thorac Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial.
Takehito Shukuya, Tetsuhiko Asao, Yasushi Goto, Tomoyasu Mimori, Koichi Takayama, Ryo Ko

Lancet Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study.
Yuichiro Nishibori, Hirotsugu Kenmotsu, Kenju Ando, Ayumi Tonsho, Suguru Matsuda, Ryo Ko

Cancer Treat Res Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of polypharmacy on the outcomes of older patients with advanced non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors: A retrospective cohort study.
Noboru Morikawa, Tateaki Naito, Meiko Morita, Motoki Sekikawa, Kosei Doshita, Ryo Ko

J Geriatr Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study.
Kosei Doshita, Tateaki Naito, Suguru Matsuda, Meiko Morita, Motoki Sekikawa, Ryo Ko

Thorac Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical potential of SKP2 as diagnostic marker and therapeutic target in small cell lung cancer.
Naohisa Matsumoto, Ken Tajima, Fumiyuki Takahashi, Yoichiro Mitsuishi, Aditya Wirawan, Ryo Ko

Respir Investig· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Meiko Morita, Akira Ono, Motoki Sekikawa, Kosei Doshita, Keita Miura, Ryo Ko

Cancer Rep (Hoboken)· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of anamorelin among patients with diabetes.
Kenju Ando, Tateaki Naito, Satoshi Hamauchi, Keita Miura, Yuichiro Nishibori, Ko Ryo

Int J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suitability of frozen cell pellets from cytology specimens for the Amoy 9-in-1 assay in patients with non-small cell lung cancer.
Hiroaki Kodama, Haruyasu Murakami, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko

Thorac Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma.
Yuko Iida, Kazushige Wakuda, Hirotsugu Kenmotsu, Kosei Doshita, Hiroaki Kodama, Ryo Ko

Sci Rep· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing.
Kazushige Wakuda, Meiko Morita, Motoki Sekikawa, Noboru Morikawa, Keita Miura, Ryo Ko

Int J Clin Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer.
Yuko Iida, Kazushige Wakuda, Takuya Kawata, Meiko Morita, Motoki Sekikawa, Ryo Ko

Thorac Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second-line chemotherapy in patients with small cell lung cancer.
Motoki Sekikawa, Haruyasu Murakami, Meiko Morita, Kosei Doshita, Keita Miura, Ryo Ko

Thorac Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101).
Tetsuhiko Asao, Takehito Shukuya, Tomoyasu Mimori, Yasushi Goto, Hiroshi Tanaka, Ryo Ko

Clin Lung Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous vs. Fixed 2-year Duration Immune Checkpoint Inhibitor Treatment of Patients With Non-Small Cell Lung Cancer: A Single Institution Database Analysis.
Haruki Kobayashi, Kazushige Wakuda, Tateaki Naito, Nobuaki Mamesaya, Ryo Ko

Clin Lung Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study.
Ryota Saito, Shunichi Sugawara, Ryo Ko, Koichi Azuma, Ryo Morita

Eur J Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma.
Koichiro Kanamori, Kentaro Suina, Takehito Shukuya, Fumiyuki Takahashi, Takuo Hayashi, Ryo Ko

Thorac Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the initial brain metastasis velocity in non-small cell lung cancer at a single cancer center.
Keisuke Kimura, Shoichi Deguchi, Koichi Mitsuya, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko

J Neurooncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis